Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma

[1]  Jae Hoon Kim,et al.  MicroRNA Expression Profiles in Serous Ovarian Carcinoma , 2008, Clinical Cancer Research.

[2]  C. Croce,et al.  MiR-15a and miR-16-1 cluster functions in human leukemia , 2008, Proceedings of the National Academy of Sciences.

[3]  T O Nielsen,et al.  MicroRNA expression signature of human sarcomas , 2008, Oncogene.

[4]  M. Loda,et al.  Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients , 2008, Modern Pathology.

[5]  A. Whittemore,et al.  Effects of Common Germ-Line Genetic Variation in Cell Cycle Genes on Ovarian Cancer Survival , 2008, Clinical Cancer Research.

[6]  D. Levine,et al.  Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma. , 2008, American journal of obstetrics and gynecology.

[7]  George A Calin,et al.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. , 2008, JAMA.

[8]  Huan Yang,et al.  MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. , 2008, Cancer research.

[9]  Tsung-Cheng Chang,et al.  Widespread microRNA repression by Myc contributes to tumorigenesis , 2008, Nature Genetics.

[10]  J. Mendell,et al.  Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. , 2007, Experimental hematology.

[11]  D. Katsaros,et al.  Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. , 2007, Cancer research.

[12]  Martin M. Matzuk,et al.  Conditional Deletion of Smad1 and Smad5 in Somatic Cells of Male and Female Gonads Leads to Metastatic Tumor Development in Mice , 2007, Molecular and Cellular Biology.

[13]  A. Mes-Masson,et al.  Construction of a chromosome 17 transcriptome in serous ovarian cancer identifies differentially expressed genes , 2007, International Journal of Gynecologic Cancer.

[14]  L. Bourguignon,et al.  Heregulin-mediated ErbB2-ERK Signaling Activates Hyaluronan Synthases Leading to CD44-dependent Ovarian Tumor Cell Growth and Migration* , 2007, Journal of Biological Chemistry.

[15]  A. Fire,et al.  Patterns of known and novel small RNAs in human cervical cancer. , 2007, Cancer research.

[16]  T. Tammela,et al.  MicroRNA expression profiling in prostate cancer. , 2007, Cancer research.

[17]  C. Croce,et al.  MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. , 2007, JAMA.

[18]  Patricia Soteropoulos,et al.  A micro‐RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas , 2007, Genes, chromosomes & cancer.

[19]  D. Whiteman,et al.  Risk Factors for Benign Serous and Mucinous Epithelial Ovarian Tumors , 2007, Obstetrics and gynecology.

[20]  R. Drapkin,et al.  Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer , 2007, Clinical Medicine & Research.

[21]  R. Berkowitz,et al.  Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship , 2007, The American journal of surgical pathology.

[22]  R. Stallings,et al.  Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. , 2007, Cancer research.

[23]  R. Drapkin,et al.  The distal fallopian tube: a new model for pelvic serous carcinogenesis , 2007, Current opinion in obstetrics & gynecology.

[24]  L. Bourguignon,et al.  Hyaluronan-CD44 Interaction with Neural Wiskott-Aldrich Syndrome Protein (N-WASP) Promotes Actin Polymerization and ErbB2 Activation Leading to β-Catenin Nuclear Translocation, Transcriptional Up-regulation, and Cell Migration in Ovarian Tumor Cells* , 2007, Journal of Biological Chemistry.

[25]  C. Croce,et al.  MicroRNA signatures in human ovarian cancer. , 2007, Cancer research.

[26]  R. Pearson,et al.  A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition. , 2006, Cancer research.

[27]  Tara L. Naylor,et al.  microRNAs exhibit high frequency genomic alterations in human cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[28]  K. Livak,et al.  Multiplexing RT-PCR for the detection of multiple miRNA species in small samples. , 2006, Biochemical and biophysical research communications.

[29]  T. Okanoue,et al.  Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues , 2006, Oncogene.

[30]  D. Cameron,et al.  Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. , 2006, Carcinogenesis.

[31]  林下 陽二.  A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation , 2006 .

[32]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.

[33]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[35]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[36]  Shuta Tomida,et al.  Reduced expression of Dicer associated with poor prognosis in lung cancer patients , 2005, Cancer science.

[37]  O. Sheils,et al.  ret/PTC and BRAF Act as Distinct Molecular, Time-Dependant Triggers in a Sporadic Irish Cohort of Papillary Thyroid Carcinoma , 2005, International journal of surgical pathology.

[38]  P. Morice,et al.  Prognosis of stage III or IV primary peritoneal serous papillary carcinoma. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[39]  Y. Yatabe,et al.  Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.

[40]  B. Modan,et al.  Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study. , 2004, American journal of obstetrics and gynecology.

[41]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[42]  Michael Z Michael,et al.  Reduced accumulation of specific microRNAs in colorectal neoplasia. , 2003, Molecular cancer research : MCR.

[43]  W. Weichert,et al.  Protein kinase C isoform expression in ovarian carcinoma correlates with indicators of poor prognosis. , 2003, International journal of oncology.

[44]  R. L. Baldwin,et al.  Molecular similarities between primary peritoneal and primary ovarian carcinomas , 2003, International Journal of Gynecologic Cancer.

[45]  V. Ambros,et al.  MicroRNA Pathways in Flies and Worms Growth, Death, Fat, Stress, and Timing , 2003, Cell.

[46]  E. Partridge,et al.  Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study. , 2003, Gynecologic oncology.

[47]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[48]  阪本健太郎.  大腸癌との鑑別が困難であった extraovarian peritoneal serous papillary carcinoma の1例 , 2002 .

[49]  M. Hung,et al.  Hyaluronan Promotes CD44v3-Vav2 Interaction with Grb2-p185HER2 and Induces Rac1 and Ras Signaling during Ovarian Tumor Cell Migration and Growth* , 2001, The Journal of Biological Chemistry.

[50]  I. Campbell,et al.  The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. , 2001, Cancer research.

[51]  I. Bukovsky,et al.  Immunohistochemical Comparison of Primary Peritoneal and Primary Ovarian Serous Papillary Carcinoma , 2001, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[52]  R. L. Baldwin,et al.  Allelotype of papillary serous peritoneal carcinomas. , 2001, Gynecologic oncology.

[53]  R. Roden,et al.  A serologically identified tumor antigen encoded by a homeobox gene promotes growth of ovarian epithelial cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[54]  M. Wells,et al.  Precursor lesions of ovarian epithelial malignancy , 2001, Histopathology.

[55]  J. Nesland,et al.  E‐cadherin and α‐, β‐, and γ‐catenin protein expression is up‐regulated in ovarian carcinoma cells in serous effusions , 2000 .

[56]  A. Saqi,et al.  Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in Müllerian serous carcinomas: clinical divergence without immunophenotypic differences. , 2000, Gynecologic oncology.

[57]  R. Berkowitz,et al.  Distinct allelic loss patterns in papillary serous carcinoma of the peritoneum. , 2000, American journal of clinical pathology.

[58]  B. Melichar,et al.  Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA‐4 on malignant ascites CD3+ tumour‐infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis , 2000, Clinical and experimental immunology.

[59]  J. Nesland,et al.  E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. , 2000, The Journal of pathology.

[60]  S. Silverberg.  Histopathologic grading of ovarian carcinoma: a review and proposal. , 2000, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[61]  M. Berlière,et al.  Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. , 1999, Human reproduction.

[62]  R. L. Baldwin,et al.  Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. , 1999, American journal of obstetrics and gynecology.

[63]  R. Berkowitz,et al.  Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum , 1998, Oncogene.

[64]  R. Berkowitz,et al.  Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. , 1998, Journal of the National Cancer Institute.

[65]  M. Piver,et al.  Extraovarian primary peritoneal carcinoma. , 1998, Oncology.

[66]  M. Piver,et al.  Epidemiologic Differences Between Women With Extraovarian Primary Peritoneal Carcinoma and Women With Epithelial Ovarian Cancer , 1998, Obstetrics and gynecology.

[67]  Worsley,et al.  Expression of E‐cadherin, α‐catenin and β‐catenin in normal ovarian surface epithelium and epithelial ovarian cancers , 1998 .

[68]  B. Ponder,et al.  Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. , 1998, Histopathology.

[69]  T. Tamaya,et al.  Expression of E-cadherin and α- and β-catenin mRNAs in ovarian cancers , 1997 .

[70]  S. Finkelstein,et al.  A case‐matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma , 1997, Cancer.

[71]  T. Tamaya,et al.  Expression of E-cadherin and alpha- and beta-catenin mRNAs in ovarian cancers. , 1997, Cancer letters.

[72]  B. Karlan,et al.  DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. , 1996, Oncogene.

[73]  J. Warwick,et al.  The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. , 1996, Cancer research.

[74]  E. Sivan,et al.  Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma. , 1996, Gynecologic oncology.

[75]  K. Tham,et al.  Papillary serous carcinoma of the peritoneum. , 1995, Journal of obstetrics and gynaecology.

[76]  R. Berkowitz,et al.  Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. , 1995, Cancer research.

[77]  P. Schwartz,et al.  Advanced ovarian carcinoma: molecular evidence of unifocal origin. , 1993, Gynecologic oncology.

[78]  F. Mitelman,et al.  Mapping of the 19p13 breakpoint in an ovarian carcinoma between the INSR and TCF3 Loci , 1993, Genes, chromosomes & cancer.

[79]  L. Bloss,et al.  Extraovarian peritoneal serous papillary carcinoma: A case‐control retrospective comparison to papillary adenocarcinoma of the ovary , 1993, Gynecologic oncology.

[80]  M. Birrer,et al.  p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. , 1993, Cancer research.

[81]  R. Berkowitz,et al.  Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas. , 1993, Gynecologic oncology.

[82]  P. Humphrey,et al.  Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. , 1992, Journal of the National Cancer Institute.

[83]  R. Knapp,et al.  Unifocal origin of advanced human epithelial ovarian cancers. , 1992, Cancer research.

[84]  D. Eccles,et al.  Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. , 1992, British Journal of Cancer.

[85]  Y. Nakamura,et al.  Allelotype of human ovarian cancer. , 1991, Cancer research.

[86]  F. Mitelman,et al.  Bilateral ovarian carcinoma: Cytogenetic evidence of unicentric origin , 1991, International journal of cancer.

[87]  Y. Nakamura,et al.  Allele losses on chromosome 17 in human epithelial ovarian carcinoma. , 1990, Oncogene.

[88]  J. H. Lee,et al.  Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas. , 1990, Cancer research.

[89]  M. Friedlander,et al.  Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases , 1989, Cancer.

[90]  M. Piver,et al.  Peritoneal papillary carcinoma. , 1988, Gynecologic oncology.

[91]  M. Swerdlow.  Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary; case report. , 1959, American journal of obstetrics and gynecology.